Pilot study of resveratrol in older adults with impaired glucose tolerance

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 67, Issue 12, 2012, Pages 1307-1312

  Crandall, Jill P ^a,b,c   Oram, Valerie ^a   Trandafirescu, Georgeta ^a,b   Reid, Migdalia ^a   Kishore, Preeti ^a,b,c   Hawkins, Meredith ^a,b,c   Cohen, Hillel W ^d   Barzilai, Nir ^a,b,c  

^a Division of Endocrinology   (United States)

^b Diabetes Research and Training Center   (United States)

^c Institute of Aging Research   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTIOXIDANT; RESVERATROL; STILBENE DERIVATIVE;

AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMAN; MALE; METABOLISM; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

AGED; ANTIOXIDANTS; BLOOD GLUCOSE; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; MALE; PILOT PROJECTS; STILBENES;

EID: 84860131782     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glr235     Document Type: Article

References (38)

1. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5:493-506. (Pubitemid 44136961)
2. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother. 2008; 62:598-605.
3. Labbe A, Garand C, Cogger V, et al. Resveratrol improves insulin resistance, hyperglycemia and hepatosteatosis but not hypertriglyceridemia, infl ammation and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci. 2011; 66:264-278.
4. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and digi survival of mice on a high-calorie diet. Nature. 2006;44:337-342. (Pubitemid 44764104)
5. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109-1122. (Pubitemid 44894520)
6. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-defi cient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59:554-563.
7. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One. 2008;3:e2264.
8. Labinskyy N, Csiszar A, Veress G, et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem. 2006;13:989-996.
9. Ungvari Z, Orosz Z, Rivera A, et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol. 2007;92: H2417-H2424. (Pubitemid 47084624)
10. Cruz MN, Luksha L, Logman H, Poston L, Agewell S, Kublickiene K. Acute responses to phytoestrogens in small arteries from men with coronary heart disease. Am J Physiol Heart Circ Physiol. 2006;290: H1969-H1975.
11. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu J. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med. 2002;9:77-79.
12. Smoliga J, Vang O, Baur JA. Challenge of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci. 2011 [Epub ahead of print].
13. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive effi cacy of resvera-trol: a conundrum. Cancer Epidemiol Biomarkers Prev. 2003;12:953-957. (Pubitemid 37310248)
14. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010;54:7-16.
15. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263-1268. (Pubitemid 44125920)
16. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
17. Crandall J, Schade D, Ma Y, et al. The infl uence of age on the effects of lifestyle modifi cation and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075-1081. (Pubitemid 44727217)
18. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 1999; 262:20-24. (Pubitemid 29412616)
19. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol. 2000;151:190-198. (Pubitemid 30463650)
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470. (Pubitemid 29418240)
21. Aloulou I, Brun JF, Mercier J. Evaluation of insulin sensitivity and glucose effectiveness during a standardized breakfast test: comparison with the minimal model analysis of an intravenous glucose tolerance test. Metabolism. 2006;55:676-690.
22. Utzschneider K, Prigeon R, Faulenbach M, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32:335-341.
23. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44:2137-2141. (Pubitemid 39576032)
24. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008; 117:2467-2474. (Pubitemid 351670453)
25. Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes. 2003; 52:1738-1748. (Pubitemid 36792465)
26. Dalla Man C, Campioni M, Polonsky KS, et al. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005; 54:3265-3273. (Pubitemid 43334384)
27. Brun JF, Ghanassia E, Fedou C, Bordenave S, Raynaud de Mauverger E, Mercier J. Assessment of insulin sensitivity (SI) and glucose effectiveness (SG) from a standardized hyperglucidic breakfast test in type 2 diabetics exhibiting various levels of insulin resistance. Acta Diabetol. 2010 [Epub ahead of print].
28. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007; 404:1-13. (Pubitemid 46788079)
29. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450:712-716. (Pubitemid 350207685)
30. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010; 285:8340-8351.
31. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32:1377-1382. (Pubitemid 39564557)
32. Brown V, Patel K, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, Metab Dispos. 2004;32:1377-1382. nol prepa
33. Crandall JP, Shamoon H, Cohen HW, et al. Post-challenge hypergly-cemia in older adults is associated with increased cardiovascular risk profile. J Clin Endocrinol Metab. 2009;94:1595-1601.
34. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 1995;235:207-219.
35. Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Sas DK. Coordinated induction of iNOS-VEGF-KDR-eNOS after resvera-trol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol. 2005;42:281-289. (Pubitemid 40726331)
36. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens. 2005;18:864-870. (Pubitemid 40745275)
37. Zern TL, Wood RJ, Greene C, et al. Grape polyphenols exert a cardio-protective effect in pre-and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;35:1911-1917. (Pubitemid 41099749)
38. Ghanim H, Sia CL, Korzeniewski K, et al. A resveratrol and polyphenol preparation suppresses oxidative and infl ammatory stress response to a high fat, high carbohydrate meal. J Clin Endocrinol Metab. 2011; 96:1409-1414.